What New GLP-1 and Obesity Medication Trials Are Happening Now (and Why They Matter)
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
The science behind weight-loss and diabetes medicines keeps moving fast. You might have heard about brand-name drugs like Wegovy or Ozempic already. What’s new is the next wave of research that could reshape treatment options in the coming year. These studies are happening now, and results are expected in 2027 or later.
Here’s what each one is studying and why it matters to you.
A Study Testing a Stronger Next-Generation Option
Trial name: TRANSCEND-T2D-2 (NCT06260722)
This study is testing a new medication called retatrutide against semaglutide, which is the ingredient in FDA-approved medications like Wegovy and Ozempic.
Semaglutide works on one hormone pathway in the body. Retatrutide works on three.
Researchers are looking at blood sugar control, weight changes, and side effects in people with type 2 diabetes.
Why we should care:
If this new medicine works better or differently, it could represent the next wave of treatment after current GLP-1 drugs.
When to watch:
The trial is expected to be completed in 2027. That means we may see study results published in late 2027 or 2028. Even if results are strong, FDA review and approval can take additional time. Real-world availability would likely be years away, not months.
A GLP-1 Pill Instead of an Injection
Trial name: ATTAIN-1 (NCT05869903)
This study is testing an oral medication called orforglipron.
Unlike Wegovy or Zepbound, which are injections, this is a pill.
Researchers are studying how well it helps with blood sugar and weight management.
Why we should care:
Many people are uncomfortable with injections. A pill that works well could make treatment feel easier and more approachable, while making GLP-1 treatments more common if more people consider it as an option.
When to watch:
The study is expected to finish in 2027. If the results are strong, the next steps would involve regulatory review. That process usually takes at least a year or more before any approval decision.
A New Weekly Injection Competing With Today’s Options
Trial name: VANQUISH-2 (NCT07104383)
This study is testing VK2735 (we can’t wait for it to have a better marketing name), a weekly injection for people with type 2 diabetes and higher body weight.
It is being studied in a large Phase 3 program, which means it is in late-stage testing.
Current medications in this space include Mounjaro and Zepbound.
Why we should care:
More competition usually leads to more choices. Over time, competition can also influence pricing and insurance coverage. Plus, another effective medication available may mean a better fit for those who aren’t responding as well to current medication options.
When to watch:
Completion is projected for 2027. If results are positive, approval discussions could follow in 2028 or later. For how long it could take to hit a pharmacy near you, this would likely take additional time.
A Study Looking at How the Body Burns Energy
Trial name: Survodutide vs Semaglutide (NCT06745284)
This study compares a medication called Survodutide with semaglutide, the ingredient in Wegovy.
Instead of only measuring weight loss, researchers are studying how the body uses energy and burns fat.
Why regular people should care:
Understanding how the body responds underneath the scale can help doctors improve dosing strategies and choose the right medication for the right person.
When to watch:
Primary completion is currently listed as early 2027. Results would likely be discussed later that year or in 2028. This type of study informs future care but does not immediately change what is available. You could hear your providers talking about it from 2028 or later
Another Late-Stage Obesity Trial Expanding the Pipeline
Trial name: RESTORE (NCT07009860)
This is a large Phase 3 study focused on obesity treatment.
It represents one of many newer medications trying to compete with established drugs like Mounjaro and Wegovy.
Why regular people should care:
Every successful late-stage study increases the number of serious competitors in the market. That matters long term for access and pricing - more medication options, more affordable options becoming available.
When to watch:
The study is expected to complete in 2027. If results are positive, regulatory steps would follow. That means meaningful changes in what you can access would likely take several years, and you’d soon see another medication on the market.
A Study Focused on Reducing Digestive Side Effects
Trial name: Probiotic Intervention in GLP-1 Users (NCT07213323)
This study is not testing a new GLP-1 medication.
Instead, it is testing whether probiotics can help reduce digestive side effects in people already taking GLP-1 drugs, making treatment potentially more effective or easier on your digestive system.
Why regular people should care:
Digestive side effects are one of the most common reasons people stop treatment. If supportive strategies help, more people may be able to stay on therapy comfortably. It also means people are more likely to be open to treatment if side effects can be controlled.
When to watch:
Estimated completion is in 2027. If the results show benefit, doctors may begin incorporating supportive strategies into care more widely, making treatments easier for those who experience side effects (we hope).
What All of This Means
When you zoom out, what’s happening here is pretty straightforward. There are a lot of new medications being tested right now. Some are trying to work better than what we already have. Some are trying to make things easier, like offering a pill instead of a shot. Others are focused on making treatment more comfortable by reducing side effects.
Most of these studies are expected to wrap up in 2027. That means we’ll likely start seeing results published around then. It doesn’t mean you’ll walk into a pharmacy in 2027 and suddenly see five new options on the shelf. After study results come out, there are still reviews, approvals, manufacturing steps, and insurance decisions that all take time, so this can feel like it’s not incredibly important right now, but it’s an important start.
Still, 2027 could be an important year because we’ll have more data. And more data often leads to more competition. Over time, competition is one of the few things that can improve access and affordability.
So this isn’t an overnight shift. It’s more like watching the next chapter slowly take shape. And for anyone following the GLP-1 space, it’s worth paying attention to what those results show.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
New GLP-1 Alzheimer’s trials found semaglutide did not slow memory loss. Learn what this means for brain health, GLP-1 users, and future research.
What’s actually changing for GLP-1 medications in 2026, what isn’t, and how new evidence is shaping care and expectations.
What will oral GLP-1 pills change about weight-loss medication use? Compare injections vs daily dosing and long-term impact.
Curated by
